SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-076339
Filing Date
2024-06-21
Accepted
2024-06-21 17:07:07
Documents
12
Period of Report
2024-06-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amlx-20240621.htm   iXBRL 8-K 51073
2 EX-10.1 amlx-ex10_1.htm EX-10.1 671359
  Complete submission text file 0000950170-24-076339.txt   932001

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT amlx-20240621.xsd EX-101.SCH 27025
15 EXTRACTED XBRL INSTANCE DOCUMENT amlx-20240621_htm.xml XML 4530
Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

IRS No.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41199 | Film No.: 241061326
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)